Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celularity (CELU) EPS (Weighted Average and Diluted) (2020 - 2025)

Celularity (CELU) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.88 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 20.55% to -$0.88 in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.33, a 172.95% decrease, with the full-year FY2024 number at -$2.64, up 76.04% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.88 for Q3 2025 at Celularity, up from -$1.02 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.08 in Q4 2022 to a low of -$11.19 in Q3 2023.
  • A 5-year average of -$1.3 and a median of -$0.66 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 115.87% in 2021, then tumbled 37400.0% in 2023.
  • Celularity's EPS (Weighted Average and Diluted) stood at $0.51 in 2021, then surged by 111.76% to $1.08 in 2022, then decreased by 22.22% to $0.84 in 2023, then plummeted by 170.24% to -$0.59 in 2024, then plummeted by 49.15% to -$0.88 in 2025.
  • Per Business Quant, the three most recent readings for CELU's EPS (Weighted Average and Diluted) are -$0.88 (Q3 2025), -$1.02 (Q2 2025), and -$0.84 (Q1 2025).